At the close on Tuesday, shares in Dublin, Ireland headquartered Endo International PLC rose 3.01%, ending the day at $19.85. The stock recorded a trading volume of 2.46 million shares. The Company's shares have advanced 10.03% in the previous three months. The stock is trading below its 50-day moving average by 6.19%. Moreover, shares of Endo International, which develops, manufactures, and distributes pharmaceutical products and devices worldwide, have a Relative Strength Index (RSI) of 43.84.
On September 29th, 2016, research firm Northland Capital upgraded the Company's stock rating from 'Market Perform' to 'Outperform'.
On October 18th, 2016, Endo International announced that it will report its Q3 2016 financial results before the open of the U.S. financial markets on November 8th, 2016, and members of its senior management team will host a conference call and webcast at 8:30 a.m. ET on the same day. ENDP complete research report is just a click away and free at:
Shares in Petach Tikva, Israel headquartered Teva Pharmaceutical Industries Ltd ended the day 3.52% higher at $43.26. A total volume of 11.07 million shares was traded, which was above their three months average volume of 6.27 million shares. The stock is trading below its 50-day moving average by 13.24%. Furthermore, shares of Teva Pharma, which develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide, have an RSI of 28.30.
On October 17th, 2016, Teva Pharma announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending an indication extension of Trisenox® (arsenic trioxide). The indication extension is for use in newly diagnosed low to intermediate risk Acute Promyelocytic Leukemia in combination with retinoic acid. Trisenox®, in combination with retinoic acid, has shown a very high overall survival rate with almost no relapses after more than four years (of median follow-up. If the European Commission approves this label extension, it would mark the first time that a form of acute leukemia can be effectively treated with a regimen that is entirely chemotherapy-free. The complimentary report on TEVA can be downloaded at:
On Tuesday, shares in Carlsbad, California headquartered Ionis Pharmaceuticals Inc. finished 0.87% lower at $28.62 with a total trading volume of 1.16 million shares. The stock has advanced 4.91% over the previous three months. The Company's shares are trading below their 50-day moving average by 13.02%. Additionally, shares of Ionis Pharma, which focuses on developing drugs for patients with severe and rare diseases, have an RSI of 30.10.
On October 8th, 2016, new data from the clinical program for nusinersen, an investigational treatment for spinal muscular atrophy (SMA), were presented by Biogen and Ionis Pharmaceuticals at the 2016 World Muscle Society Congress in Granada, Spain. The presentations included safety results from the interim analysis of the Phase 3 ENDEAR study in infantile-onset SMA, encouraging preliminary results from NURTURE, a Phase 2 open-label study in pre-symptomatic infants, and a recent analysis of the ongoing Phase 2 open-label study in patients with later-onset SMA. Sign up for your complimentary research report on IONS at:
Universal Health Services
King of Prussia, Pennsylvania headquartered Universal Health Services Inc.'s shares recorded a trading volume of 843,666 shares at the end of yesterday's session, which was higher than their three months average volume of 821,030 shares. The stock closed the day at $125.85, gaining 1.94%. The Company's shares have advanced 2.09% in the last one month and 5.58% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 3.04% and 1.84%, respectively. Additionally, shares of Universal Health Services, which through its subsidiaries, owns and operates acute care hospitals, behavioral health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers, have an RSI of 61.58.
On October 14th, 2016, Universal Health Services announced that it will report results for its Q3 ended September 30th, 2016, after the market closes on October 26th, 2016. The company will host a conference call for investors and analysts at 9:00 a.m. ET on October 27th, 2016. Get free access to your research report on UHS at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA